Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background Episodes of depression are the most frequent cause of disability among patients with bipolar disorder. The effectiveness and safety of standard antidepressant agents for depressive episodes associated with bipolar disorder (bipolar depression) have not been well studied. Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania. Methods In this double-blind, placebo-controlled study, we randomly assigned subjects with bipolar depression to receive up to 26 weeks of treatment with a mood stabilizer plus adjunctive antidepressant therapy or a mood stabilizer plus a matching placebo, under conditions generalizable to routine clinical care. A standardized clinical monitoring form adapted from the mood-disorder modules of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, was used at all follow-up visits. The primary outcome was the percentage of subjects in each treatment group meeting the criterion for a durable recovery (8 consecutive weeks of euthymia). Secondary effectiveness outcomes and rates of treatment-emergent affective switch (a switch to mania or hypomania early in the course of treatment) were also examined. Results Forty-two of the 179 subjects (23.5%) receiving a mood stabilizer plus adjunctive antidepressant therapy had a durable recovery, as did 51 of the 187 subjects (27.3%) receiving a mood stab…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on negative placebo‐controlled data, we do not recommend paroxetine (level 2 negative).245”
In the citing paper
“Antimanic medications reduce depressive symptoms in only one-third of patients (2).”
From Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial (2018) · cites this paper as [2]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
Kane, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.1 · Cited by 987
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationPerlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Self-citationPrevalence and Treatment of Mental Disorders
(2005) · New England Journal of Medicine · doi:10.1056/nejmc051936 · Cited by 650
Research works printed but not linked: 4
- Murray CJ, 1994, Bull World Health Organ, 72, 495
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
- Sachs GS, 1994, J Clin Psychiatry, 55, 391
- 10.1037/0021-843X.108.4.579 · doi:10.1037/0021-843x.108.4.579 · Paper page
Cited by
Items 201–300 of 935
Balancing benefits and harms of treatments for acute bipolar depression
Ketter, T. A., Miller, S., Dell'Osso, B., Calabrese, J. R., Frye, M. A., & Citrome, L. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70006-0 · Cited by 47
“, 2003) and another contributed approximately 32% of the patients (Sachs et al., 2007), so that the remaining 4 studies accounted for only approximately 26% of all patients (Amsterdam and Shults, 2005; Cohn et al.”
BackgroundSelf-citationUnipolar and bipolar depression: different or the same?
Smıth, D. J., & Craddock, N. J. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.092726 · Cited by 50
“18 Mitchell and colleagues suggest that identifying bipolarity in patients with major depressive disorder will be helpful for future genetic studies but identifying these patients might also be useful in the assessment of new treatments for depression (both pharmacological and psychological) by…”
Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors
Fung, V., Overhage, L., Sylvia, L. G., Reilly-Harrington, N. A., Kamali, M., Gao, K., Shelton, R. C., Ketter, T. A., Bobo, W. V., Thase, M. E., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.050 · Cited by 51
Self-citationReducing the Hypomania Checklist (HCL-32) to a 16-item version
Forty, L., Kelly, M. J., Jones, L. A., Jones, I. R., Barnes, E., Caesar, S., Fraser, C., Gordon‐Smith, K., Griffiths, E., Craddock, N. J., et al. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.01.004 · Cited by 49
Historical Underpinnings of Bipolar Disorder Diagnostic Criteria
Mason, B. L., Brown, E. S., & Croarkin, P. E. (2016) · Behavioral Sciences · doi:10.3390/bs6030014 · Cited by 74
“Importantly, the STEP-BP study indicated that adjunctive treatment of antidepressants with mood stabilizers was not associated with greater efficacy nor a greater risk for an affective switch [32] and that adjunctive treatment with lamotrigine, inositol, or risperidone to antidepressant treatment provided no significa…”
ResultHamoda, H. M., & Osser, D. N. (2008) · Harvard Review of Psychiatry · doi:10.1080/10673220802277904 · Cited by 47
Hallam, K. T., Smith, D. I., & Berk, M. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.024 · Cited by 46
Refractoriness in Bipolar Disorder: Definitions and Evidence‐Based Treatment
Fountoulakis, K. N. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00259.x · Cited by 44
“However, paroxetine failed not only during the STEP-BD trial [92], but also in two RCTs [93,94].”
ResultRYBAKOWSKI, J. K. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.005 · Cited by 50
Mechri, A., Kerkeni, N., Touati, I., Bacha, M., & Gassab, L. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.02.006 · Cited by 45
“…lead to inappropriate treatments, such as antidepressants as monotherapy (i.e. not combined with mood stabilizers) which in patients with bipolar depression may not only be less effective (Sachs et al., 2007) but also have an increased risk of a manic switch or cycle acceleration (Bowden, 2005).”
BackgroundTreatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
Ketter, T. A., Citrome, L., Wang, P. W., Culver, J. L., & Srivastava, S. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01645.x · Cited by 49
“Although there are scant controlled data regarding the utility of medications in the heterogeneous groups of bipolar disorder patients with complex psychiatric and medical comorbidities who are already receiving complex combination therapies that are commonly encountered in clinical practice, comparative effectiveness…”
BackgroundSelf-citationAssessing Childhood Psychopathology and Developmental Disabilities
Matson, J. L., Andrasik, F., & Matson, M. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-09528-8 · Cited by 50
Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change
Martínez‐Arán, A., Vieta, E., Chengappa, K. R., Gershon, S., Mullen, J., & Paulsson, B. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00611.x · Cited by 48
Antidepressants in Bipolar I Disorder: Never as Monotherapy
Vieta, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14070826 · Cited by 51
A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression
Zheng, W., Zhou, Y.-L., Liu, W.-J., Wang, C.-Y., Zhan, Y.-N., Lan, X.-F., Zhang, B., & Ning, Y.-P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.06.020 · Cited by 44
Shah, M. S., Khan, S. U., Ejaz, S. A., Afridi, S., Rizvi, S. U. F., Haq, M. N. U., & Iqbal, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.082 · Cited by 44
Takeshima, M., Utsumi, T., Aoki, Y., Wang, Z., Suzuki, M., Okajima, I., Watanabe, N., Watanabe, K., & Takaesu, Y. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12976 · Cited by 43
“Antidepressant monotherapy increases manic switching,(47) whereas a combination of antidepressants and mood stabilizers does not.(48) As BLT is believed to have the same mechanism of enhancing serotonin levels that most antidepressants have,(49,50) BLT without mood stabilizers may increase manic switching.”
BackgroundDean, O. M., Turner, A., Malhi, G. S., Ng, C., Cotton, S. M., Dodd, S., Sarris, J., Samuni, Y., Tanious, M., Dowling, N., et al. (2014) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-1341 · Cited by 43
Wirz‐Justice, A. (2007) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.08.003 · Cited by 53
Biernacka, J. M., McElroy, S. L., Crow, S. J., Sharp, A., Benitez, J., Veldić, M., Kung, S., Cunningham, J. M., Post, R. M., Mrazek, D. A., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.038 · Cited by 43
“…treatment is generally effective (Gijsman et al., 2004), large controlled trials of paroxetine monotherapy and adjunctive paroxetine or bupropion reported response rates that were no better than placebo or mood stabilizer alone, respectively (McElroy et al., 2010; Sachs et al., 2007).”
BackgroundAchtyes, E. D., Halstead, S., Smart, L., Moore, T., Frank, E., Kupfer, D. J., & Gibbons, R. (2015) · Psychiatric Services · doi:10.1176/appi.ps.201400390 · Cited by 43
Bipolar disorder: candidate drug targets
Zarate, C. A., & Manji, H. K. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20042 · Cited by 45
Dunn, R. T., Stan, V. A., Chriki, L. S., Filkowski, M. M., & Ghaemi, S. N. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.01.004 · Cited by 42
Lithium in bipolar and other affective disorders: prescribing practice in the UK
Paton, C., Barnes, T. R. E., Shingleton‐Smith, A., McAllister-Williams, H., Kirkbride, J. B., Jones, P. B., & McIntyre, S. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110367728 · Cited by 45
“This is despite the most recent evidence finding no support for the efficacy of antidepressants (at least SSRIs and bupropion) in bipolar depression (Sachs, 2007).”
ResultParikh, S. V., LeBlanc, S. R., & Ovanessian, M. M. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500304 · Cited by 43
Polypharmacy and bipolar disorder: what's personality got to do with it?
Sachs, G. S., Peters, A. T., Sylvia, L., & Grunze, H. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000953 · Cited by 45
Self-citationVan Der Loos, M. L. M., Mulder, P., Hartong, E. G. T. M., Blom, M. B. J., Vergouwen, A. C., Van Noorden, M. S., Timmermans, M. A., Vieta, E., Nolen, W. A., & for the LamLit Study Group (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01537.x · Cited by 41
“carbamazepine, atypical antipsychotics and ⁄or additional psychotherapy (as in the STEP-BD add-on study of the efficacy of add-on treatment with antidepressants including the SSRI sertraline) (12) To find an answer to this question, one might consider a three-arm RCT comparing the addition of both lamotrigine and paro…”
BackgroundMitochondrial Agents for Bipolar Disorder
Pereira, C., Chavarria, V., Vian, J., Ashton, M. M., Berk, M., Marx, W., & Dean, O. M. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy018 · Cited by 40
“…et al., 2006), the treatment of bipolar depression is more challenging, as these agents may not improve depressive symptoms (Calabrese et al., 2007; Sachs et al., 2007), and treatment with antidepressants may induce phase switching, particularly with monotherapy (Post et al., 2006; Viktorin…”
Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder
Altamura, A. C., & Goikolea, J. M. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2703 · Cited by 41
“Outcomes of bipolar disorder can also be negatively infl uenced by incorrect administration of mood stabilizers and antidepressants (Goldberg et al 2007), and rapid cycling can be induced or worsened by antidepressants in the absence of a mood stabilizer (Sachs et al 2007).”
Antidepressants in bipolar depression
Vieta, E. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01233.x · Cited by 43
“As a consequence of all this, we are still uncertain on whether antidepressants are effective (3), ineffective (4), safe (5) or unsafe (6) in bipolar depression, and they might end up being the four things at the same time, depending on their class, particular pharmacodynamics, and concomitant therapy (7, 8).”
BackgroundDepression and Suicidality Outcomes in the Treatment of Early Age Mania Study
Salpekar, J. A., Joshi, P. T., Axelson, D., Reinblatt, S. P., Yenokyan, G., Sanyal, A., Walkup, J. T., Vitiello, B., Luby, J. L., Wagner, K. D., et al. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.09.016 · Cited by 41
RYBAKOWSKI, J. K., Dudek, D., Pawłowski, T., Łojko, D., Siwek, M., & Kiejna, A. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.12.001 · Cited by 42
“Generally, the use of antidepressant drugs in bipolar depression is, by many authors not now considered as the first line choice and, a paper from the STEP-BD study questioned the efficacy of these drugs in this condition [20].”
ResultQuante, A., Zeugmann, S., Luborzewski, A., Schommer, N. C., Langosch, J. M., Born, C., Anghelescu, I. G., & Wolf, J. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1096 · Cited by 45
Kemp, D. E., Gao, K., Fein, E. B., Chan, P. K., Conroy, C., Obral, S., Ganocy, S. J., & Calabrese, J. R. (2012) · Bipolar Disorders · doi:10.1111/bdi.12013 · Cited by 39
“Similar to other effectiveness studies that utilized broad entry criteria, the resulting sample heterogeneity detracted from an ability to detect any relevant between-group differences [(31); submitted manuscript: Nierenberg AA, Friedman ES, Bowden CL et al.”
ResultSelf-citationMazzarini, L., Kotzalidis, G. D., Piacentino, D., Rizzato, S., Angst, J., Azorin, J., Bowden, C. L., Mosolov, S. N., Young, A. H., Vieta, E., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.062 · Cited by 40
Self-citationEfficacy and tolerability of treatments for bipolar depression
Vázquez, G. H., Holtzman, J. N., Tondo, L., & Baldessarini, R. J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.016 · Cited by 42
“References: a. Cohn et al. 1989; Nemeroff et al. 2001; Agosti and Stewart, 2007; Sachs et al. 2007; McElroy et al. 2010. b. Calabrese et al. 1999; Davis et al. 2005; Ghaemi et al. 2007; Zhang et al. 2007; Bond et al. 2010; Muzina et al. 2011; Reid et al. 2013. c. Young et al. 2010. d. Tohen et al.…”
Post, R. M., Leverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T., McElroy, S. L., Keck Jr, P. E., Nolen, W. A., Rowe, M., Kupka, R. W., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07396 · Cited by 38
Chronic Administration of Lamotrigine Downregulates COX-2 mRNA and Protein in Rat Frontal Cortex
Lee, H., Ertley, R. N., Rapoport, S. I., Bazinet, R. P., & Rao, J. S. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9526-3 · Cited by 44
“In contrast, classical antidepressants do not appear to add to efficacy of treatment [36], and frequently switch the depressive state to mania when administered alone to bipolar patients.”
BackgroundUse of “Lights” for Bipolar Depression
Sit, D., & Haigh, S. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1025-0 · Cited by 37
Rating Scales in Bipolar Disorder
Sajatovic, M., Chen, P., & Young, R. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00009-9 · Cited by 57
Factors associated with initial treatment response with antidepressants in bipolar disorder
Pacchiarotti, I., Valentí, M., Bonnín, C. D. M., Rosa, A. R., Murru, A., Kotzalidis, G. D., Nivoli, A., Sánchez‐Moreno, J., Vieta, E., & Colom, F. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.10.002 · Cited by 40
Stange, J. P., Sylvia, L. G., da Silva Magalhães, P. V., Miklowitz, D. J., Otto, M. W., Frank, E., Yim, C., Berk, M., Dougherty, D. D., Nierenberg, A. A., et al. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.162073 · Cited by 36
Self-citationLamotrigine-associated rash: to rechallenge or not to rechallenge?
Lorberg, B. A., Youssef, N. A., & Bhagwagar, Z. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009504 · Cited by 39
Current landscape, unmet needs, and future directions for treatment of bipolar depression
Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70005-9 · Cited by 36
Amsterdam, J. D., Wang, G., & Shults, J. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01462.x · Cited by 36
“(38) examined the durable recovery rate and comparative mood conversion rate of adjunctive bupropion vs.”
BackgroundInfluentialA pilot study of brexpiprazole for bipolar depression
Brown, E. S., Khaleghi, N., Enkevort, E. A. V., Ivleva, E. I., Nakamura, A., Holmes, T., Mason, B. L., & Escalante, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.056 · Cited by 38
Tee, M. M. K., & Au, C. W. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09822-6 · Cited by 40
Predictors of switch from depression to mania in bipolar disorder
Niitsu, T., Fabbri, C., & Serretti, A. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.014 · Cited by 40
“Indeed, some randomized controlled trials (RCTs) suggested that a mood stabilizer plus adjunctive AD therapy, comparedwith a mood stabilizer plus a placebo or mood stabilizer monotherapy, showed no association with higher risk of AD-emergent affective switch (Keck et al., 2005; Sachs et al., 2007).”
BackgroundMedicaid Prescription Drug Policies and Medication Access and Continuity: Findings From Ten States
West, J. C., Wilk, J. E., Rae, D. S., Muszynski, I. L., Stipec, M. R., Alter, C. L., Sanders, K., Crystal, S., & Regier, D. A. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.5.601 · Cited by 36
Post, R. M., Leverich, G. S., Kupka, R., Keck, P. E., McElroy, S. L., Altshuler, L. L., Frye, M. A., Rowe, M., Grunze, H., Suppes, T. M., et al. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.01.009 · Cited by 37
Clinical assessment and crisis intervention for the suicidal bipolar disorder patient
Saunders, K. E., & Hawton, K. (2013) · Bipolar Disorders · doi:10.1111/bdi.12065 · Cited by 34
“However, the role of antidepressants remains controversial (56), with little evidence to support their efficacy (56), and much of the rationale behind their use relies on their evidence base in unipolar depression.”
BackgroundBarbuti, M., Menculini, G., Verdolini, N., Pacchiarotti, I., Kotzalidis, G. D., Tortorella, A. A. V., Vieta, E., & Perugi, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.04.013 · Cited by 40
The common adolescent bipolar phenotype shows positive biases in emotional processing
Rock, P. L., Goodwin, G. M., & Harmer, C. J. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00859.x · Cited by 44
Monitoring lithium therapy: the impact of a quality improvement programme in the UK
Paton, C., Adroer, R., & Barnes, T. R. E. (2013) · Bipolar Disorders · doi:10.1111/bdi.12128 · Cited by 34
“Signs and symptoms of lithium toxicity 178 (45) 183 (38) 380 (61)”
BackgroundResultBerk, M., Tiller, J. W. G., Zhao, J., Yatham, L. N., Malhi, G. S., & Weiller, E. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08827 · Cited by 34
A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression
Park, L. T., Lener, M. S., Hopkins, M., Iadorola, N., Machado-Vieira, R., Ballard, E., Nugent, A., & Zarate, C. A. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000693 · Cited by 33
“This study was a randomized, double-blind, parallel-group trial designed to assess the efficacy and safety of riluzole (50–200 mg/d) compared with placebo in patients with BDep.”
BackgroundInfluentialBschor, T., Angst, J., Azorin, J., Bowden, C. L., Perugi, G., Vieta, E., Young, A. H., & Krüger, S. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.03.042 · Cited by 37
“in contrast to unipolar disorders, bipolar affective disorders practically always recur, therefore justifying long-term prophylaxis (Judd and Akiskal, 2003), untreated manic phases can lead to substantial negative consequences and therapeutic concepts for bipolar depression differ relevantly from those for unipolar de…”
BackgroundSelf-citationDifferentiating Bipolar Disorders from Major Depressive Disorders: Treatment Implications
Muzina, D. J., Kemp, D. E., & McIntyre, R. S. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701653591 · Cited by 37
Kirshenbaum, G. S., Burgess, C. R., Déry, N., Fahnestock, M., Peever, J. H., & Roder, J. C. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2013.12.011 · Cited by 33
Revised Korean medication algorithm for bipolar disorder
Jon, D., Bahk, W., Yoon, B. H., Shin, Y. C., Cho, H. S., Lee, E. M., Ha, K., Kim, W. K., Chung, S. K., Seo, J. S., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802144865 · Cited by 35
“A recent randomized controlled study found that for depressed bipolar I or II patients, MS monotherapy was no better or worse than combination therapy of an MS and an AD (Sachs et al. 2007).”
BackgroundLin, Y., Mojtabai, R., Goes, F. S., & Zandi, P. P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.063 · Cited by 37
Risk of Suicidal Behavior With Antidepressants in Bipolar and Unipolar Disorders
Leon, A. C., Fiedorowicz, J. G., Solomon, D. A., Li, C., Coryell, W. H., Endicott, J., Fawcett, J., & Keller, M. B. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08744 · Cited by 36
Datto, C., Pottorf, W. J., Feeley, L., LaPorte, S., & Liss, C. (2016) · Annals of General Psychiatry · doi:10.1186/s12991-016-0096-0 · Cited by 32
“For example, antidepressant monotherapy in patients with bipolar depression is associated with elevated rates of mood switch to mania [14–16], while the use of antidepressants as adjunctive therapy to mood stabilizers does not appear to be associated with increased efficacy in bipolar depression [17].”
BackgroundBroadening the diagnosis of bipolar disorder: benefits vs. risks
Strakowski, S. M., Fleck, D. E., & Maj, M. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00046.x · Cited by 34
“However, considerable controversy rages about the level of this risk, with recent data from the large STEP-BD study suggesting that newer antidepressants do not impart these risks in bipolar I or II depression (24).”
ResultCo-occurring Conditions and Health-Related Quality of Life in Patients With Bipolar Disorder
Kilbourne, A. M., Perron, B. E., Mezuk, B. R., Welsh, D. E., Ilgen, M. A., & Bauer, M. S. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181b49948 · Cited by 39
“However, the treatment of depression is difficult and recent results indicated that adjunctive antidepressant treatment may not significantly decrease depressive symptoms in those with bipolar disorder (33).”
ResultLong-Term Use of Pramipexole in Bipolar Depression: A Naturalistic Retrospective Chart Review
El‐Mallakh, R. S., Penagaluri, P., Kantamneni, A., Gao, Y., & Roberts, R. J. (2010) · Psychiatric Quarterly · doi:10.1007/s11126-010-9130-6 · Cited by 32
“Antidepressants have been used in adjunct with mood stabilizers to treat depression, but this strategy may not be effective [21, 22, 25].”
BackgroundLipsman, N., McIntyre, R. S., Giacobbe, P., Torres, C. V., Kennedy, S. H., & Lozano, A. M. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00868.x · Cited by 37
Kagawa, S., Mihara, K., Nakamura, A. M., Nemoto, K., Suzuki, T., Nagai, G., & Kondo, T. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000088 · Cited by 32
“The inclusion criteria were (1) major depressive disorder, bipolar I disorder, or bipolar II disorder according to the Diagnostic and Statistical Manual of Mental Disorder, fourth edition(9); (2) insufficient response to at least 3 psychotropics including antidepressants, mood stabilizers, or atypical antipsychotics d…”
MethodTreatment of bipolar depression: making sensible decisions
Citrome, L. (2014) · CNS Spectrums · doi:10.1017/s109285291400056x · Cited by 38
“Moreover, when comparing groups of patients receiving adjunctive antidepressant treatment vs adjunctive placebo together with a mood stabilizer, antidepressants do not confer a treatment advantage for either transient or enduring response.(16) In addition to the MDQ, additional clues that would increase one’s index of…”
ResultCombined treatment: impact of optimal psychotherapy and medication in bipolar disorder
Parikh, S. V., Hawke, L. D., Velyvis, V., Zaretsky, A., Beaulieu, S., Patelis‐Siotis, I., MacQueen, G., Young, L. T., Yatham, L. N., & Cervantes, P. (2015) · Bipolar Disorders · doi:10.1111/bdi.12233 · Cited by 31
“Both treatments were evidence-based, manualized interventions designed for bipolar disorder and delivered by trained, experienced psychiatric staff, who recorded the sessions and received ongoing supervision as required, with good treatment fidelity as reported earlier (7).”
BackgroundBahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720970857 · Cited by 31
“For example, the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) trial from 2007 did not differentiate outcomes with paroxetine versus bupropion.(48) A related problem is the notorious spate of failed versus negative RCTs in bipolar depression, such as the 2 failed aripiprazole trials,(49) the…”
ResultInternational Consensus Group on Depression Prevention in Bipolar Disorder
Frye, M. A., Ha, K., Kanba, S., Kato, T., McElroy, S. L., Özerdem, A., Vázquez, G., & Vieta, E. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10123co1c · Cited by 31
Zhang, Y., Yang, H., Yang, S., Liang, W., Dai, P., Wang, C., & Zhang, Y. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.31.009 · Cited by 36
“After screening the full text, 14 randomized controlled trials [39-52] (n = 1 244) were available for meta-analyses.”
InfluentialN- methyl-D-aspartate Glutamate Receptor Antagonists and the Promise of Rapid-Acting Antidepressants
Krystal, J. H. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.138 · Cited by 35
Tamayo, J. M., Sutton, V. K., Mattei, M. A., Diaz, B., Jamal, H. H., Vieta, E., Zarate, C. A., Fumero, I., & Tohen, M. F. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ad223f · Cited by 31
Paterniti, S., & Bisserbe, J. C. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-211 · Cited by 32
“Such negative effects appear to be limited to certain classes of antidepressants [59-61].”
BackgroundThe broad clinical spectrum of bipolar disorder: implications for research and practice
Smıth, D. J., Ghaemi, S. N., & Craddock, N. J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089585 · Cited by 32
Mendlewicz, J., Massat, I., Linotte, S., Kasper, S. F., Konstantinidis, A., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., & Souery, D. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833c4ceb · Cited by 34
“This paucity of data may explain the remaining controversies on the use of AD as adjunctive therapy to mood stabilizers (Sachs et al., 2007) and their effects on mood switches and suicidality (Thase, 2005; Bauer et al., 2006).”
BackgroundBareš, M., Novák, T., Brunovský, M., Kopeček, M., Stopková, P., Krajča, V., & Höschl, C. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.09.006 · Cited by 30
RYBAKOWSKI, J. K., Angst, J., Dudek, D., Pawłowski, T., Łojko, D., Siwek, M., & Kiejna, A. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0030-4 · Cited by 33
“In the context of this, it should be mentioned that the use of antidepressant drugs in bipolar depression is now by many authors not considered as the first line choice and some papers even question the efficacy of these drugs in such condition [17].”
BackgroundTowards the clinical implementation of pharmacogenetics in bipolar disorder
Salloum, N. C., McCarthy, M. J., Leckband, S. G., & Kelsoe, J. R. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-90 · Cited by 34
“Although controversial [89], SSRIs are widely used in conjunction with mood stabilizers or antipsychotics for depression in BD, appearing in evidence-based psychopharmacology guidelines [90,91].”
BackgroundFornaro, M., Martino, M., Pasquale, C. D., & Moussaoui, D. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.719877 · Cited by 31
“[53] and a 2008 updated meta-analysis by Ghaemi et al.”
BackgroundZhang, Z., Tan, Q., Tong, Y., Li, Q., Kang, W.-H., Zhen, X.-C., & Post, R. M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.11.004 · Cited by 30
The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances
Hirschowitz, J., Kolevzon, A., & Garakani, A. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.507042 · Cited by 33
Long-Term Worsening of Bipolar Disorder Related with Frequency of Antidepressant Exposure
Strejilevich, S. A., Martino, D. J., Marengo, E., Igoa, A., Fassi, G., Whitham, E. A., & Ghaemi, S. N. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300305 · Cited by 29
Predictors of later bipolar disorder in patients with subthreshold symptoms
Homish, G. G., Marshall, D., Dubovsky, S. L., & Leonard, K. E. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.06.020 · Cited by 32
“Most of these patients are treated with antidepressants, which have not been found to be more effective than placebo for bipolar depression (Ghaemi et al., 2003; Sachs et al., 2007) and which have the potential to destabilize bipolar disorder, especially if any residual hypomanic symptoms are present (Ghaemi et al.”
BackgroundMood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression
Nugent, A. C., Carlson, P. J., Bain, E., Eckelman, W. C., Herscovitch, P., Manji, H. K., Zarate, C. A., & Drevets, W. C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113499204 · Cited by 34
“In randomized, controlled clinical trials of bipolar depression, subjects receiving lithium plus placebo showed rates of improvement and durable recovery that did not differ significantly from those seen in subjects receiving lithium plus conventional antidepressant agents (Nemeroff et al., 2001; Sachs et al., 2007).”
Allain, N., Leven, C., Falissard, B., Allain, J., Batail, J.-M. V., Polard, É., Montastruc, F., Drapier, D., & Naudet, F. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12672 · Cited by 33
“not confirmed that all participants were depressed, and the proportion of subjects with depression was not clearly defined; (ii) the two other studies (14, 22) were derived from the same program (the STEP-BD program), and there may have been some overlap of subjects in the two studies (i.”
ResultZiprasidone monotherapy in bipolar II depression: An open trial
Liebowitz, M. R., Salmán, E., Mech, A. W., Dünner, D. L., Johnson, A. E., Akhtar, J., & Pratap, R. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.022 · Cited by 29
“(Calabrese et al., 2005; Farrelly et al., 2007; Sachs et al., 2007; Thase et al., 2008; Tohen et al., 2003).”
Treatment of Bipolar Depression
Belmaker, R. H. (2007) · New England Journal of Medicine · doi:10.1056/nejme078042 · Cited by 29
DellaCrosse, M., Pleet, M., Morton, E., Ashtari, A., Sakai, K., Woolley, J., & Michalak, E. (2022) · PLOS ONE · doi:10.1371/journal.pone.0279073 · Cited by 28
Muzina, D. J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00713.x · Cited by 32
“However this issue remains controversial, particularly given recent findings that adjunctive antidepressants do not cause mania or cycle acceleration among patients with bipolar depression, although significant benefit from antidepressant use was also not observed over placebo (14).”
ResultEarly report on brain arousal regulation in manic vs depressive episodes in bipolar disorder
Wittekind, D. A., Spada, J., Gross, A., Hensch, T., Jawinski, P., Ulke, C., Sander, C., & Hegerl, U. (2016) · Bipolar Disorders · doi:10.1111/bdi.12440 · Cited by 30
“Comparison of the groups revealed that manic patients had the lowest vigilance level, with the mean vigilance values being significantly lower than in the control sample [F(1,45) = 4.”
BackgroundResultMood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Henter, I. D., SOUSA, R. T. D., Gold, P. W., Brunoni, A. R., Zarate, C. A., & Machado‐Vieira, R. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1253472 · Cited by 31
“or BD-II depression [2] and, to date, no agent has been developed specifically to treat bipolar depression.”
BackgroundDiscriminating bipolar depression from major depressive disorder with polygenic risk scores
Liebers, D. T., Pirooznia, M., Ganna, A., (BiGS), B. G. S., & Goes, F. S. (2020) · Psychological Medicine · doi:10.1017/s003329172000015x · Cited by 30
“, 2018) which can result in misdiagnosis on initial presentation, potentially leading to the initiation of treatments of limited efficacy (Sachs et al., 2007) that may also be associated with iatrogenic harm (Baldessarini et al.”
BackgroundNoori, N., Bangash, M., Motaghinejad, M., Hosseini, P., & Noudoost, B. (2014) · Advanced Biomedical Research · doi:10.4103/2277-9175.146377 · Cited by 27
“Antidepressant medications that work on serotonin levels, such as SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs) are thought to reduce the symptoms of depression.[28,29] We can argue our finding with the basic concept that kefir as a rich food supplement has a high level of tryptophan that can be c…”
Hellerstein, D. J., & Flaxer, J. M. (2015) · Core evidence · doi:10.2147/ce.s54075 · Cited by 30
“40 Evidence in published studies to date for newly introduced medications, such as vilazodone or vortioxetine, although limited, does not yet provide convincing support for significantly improved efficacy compared to existing SSRI/SNRI medications.”
Machado‐Vieira, R., & Zarate, C. A. (2011) · Depression and Anxiety · doi:10.1002/da.20800 · Cited by 30
“[4] Similarly, a largescale study funded by the National Institute of Mental Health (NIMH) failed to find significant benefit to adding antidepressants to mood stabilizers in patients with BPD-I or II depression over the course of 26 weeks.[4,5] Thus, the development of new, effective, and better-tolerated therapeutic…”
BackgroundFornaro, M., Anastasia, A., Monaco, F., Novello, S., Fusco, A., Iasevoli, F., Berardis, D. D., Veronese, N., Solmi, M., & de Bartolomeis, A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.085 · Cited by 27
Tokumitsu, K., Yasui‐Furukori, N., Adachi, N., Kubota, Y., Watanabe, Y., Miki, K., Azekawa, T., Edagawa, K., Katsumoto, E., Hongo, S., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02967-5 · Cited by 29
Metadata
- Authors
- Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., Ketter, T. A., Patel, J., Hauser, P., Rapport, D., Martinez, J. M., Allen, M. H., Miklowitz, D. J., Otto, M. W., Dennehy, E. B., & Thase, M. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- University Hospitals Cleveland Medical Center (US)
- Baylor College of Medicine (US)
- University of Pittsburgh (US)
- University of Pennsylvania (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Oklahoma (US)
- Stanford Medicine (US)
- University of Massachusetts Chan Medical School (US)
- University of Toledo (US)
- University of Colorado Boulder (US)
- Boston University (US)
- Purdue University West Lafayette (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-26
- Volume
- 356
- Issue
- 17
- Pages
- 1711-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166423384
- Semantic Scholar
- c224a40d0ffd6471e7b72b38060d169ba1cdec34
- Cited by
- 937
- References
- 27
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 33 · 2023: 17 · 2022: 15 · 2021: 68 · 2020: 33 · 2019: 29 · 2018: 36 · 2017: 28 · 2016: 53 · 2015: 47 · 2014: 51 · 2013: 52 · 2012: 61
- FWCI
- 56.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh80001-12-0-0)
- National Institute of Mental Health (N01-MH80001)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- bipolar depression, adjunctive antidepressant therapy, mood stabilizers, euthymia, bipolar disorder, antidepressant safety
- MeSH terms
- Adult, Bipolar Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Bupropion, Treatment Outcome, Paroxetine, Antidepressive Agents, Second-Generation, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.